FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385698049> ?p ?o ?g. }

• W4385698049 endingPage "e16622f0" @default.
• W4385698049 startingPage "e16622f0" @default.
• W4385698049 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Data from the ongoing phase 2 MagnetisMM-3 (NCT04649359) study demonstrated the efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and no prior BCMA-directed therapy (Cohort A). Aims: To report the efficacy and safety of elranatamab in high-risk subgroups in BCMA-naïve patients from MagnetisMM-3. Methods: Eligibility criteria, dosing and administration were previously reported (Bahlis, ASH 2022). Subgroups analyzed were Revised International Staging System (R-ISS) stage (I/II/III), cytogenetic abnormalities (standard/high risk [high-risk defined by the presence of t(4;14), t(14;16) or del(17p)]), extramedullary disease (EMD) at baseline (Y/N), bone marrow plasma cell involvement (BMPC) at baseline (<50%/≥50%), and penta-refractory disease (Y/N). Results include data up through ~12 months after last patient initial dose. Results: Median treatment durations and the proportions of patients receiving treatment at the data cut-off were lower for all high-risk subgroups than the corresponding lower-risk subgroups (Table). The most frequent cause of discontinuation was progressive disease which was higher for all high-risk subgroups than the corresponding lower risk subgroups. A clinical benefit, assessed by the objective response rate (ORR), was observed across subgroups (Table). A multivariable logistic regression analysis for ORR including baseline age, Eastern Cooperative Oncology Group, sex, region, cytogenetic risk, presence of EMD, BMPC involvement, prior stem cell transplant, R-ISS stage, number of prior lines, type of myeloma, and penta-refractory disease showed presence of EMD at baseline and non-IgG myeloma (vs IgG) as predictive of lower ORR. Light chain-only myeloma (vs IgG) was predictive of higher ORR. Median duration of response (DOR) was not reached in subgroups by 12 months, DOR rate at 12 months is reported in the Table. Any-grade treatment-emergent adverse events (TEAEs) were reported in 100% of patients in the study. The incidence of grade 3/4 TEAEs was overall similar across subgroups (Table). Summary/Conclusion: Elranatamab is efficacious and has a manageable safety profile in patients with high-risk RRMM and no prior BCMA-directed therapy. Table - R-ISS stage I R-ISS stage II R-ISS stage III Standard cytogenetic risk High cytogenetic risk (n=28) (n=68) (n=19) (n=83) (n=31) Median treatment duration (mo) 10.7 5.7 1.4 7.9 2.6 Receiving treatment at data cut-off (%) 42.9 38.2 5.3 41.0 19.4 ORR (%, 95% CI) 75.0 63.2 26.3 63.9 54.8 (55.1, 89.3) (50.7, 74.6) (9.1, 51.2) (52.6, 74.1) (36.0, 72.7) DOR rate at 12 mo (%, 95% CI) 76.2 78.8 53.3 79.4 57.0 (45.4, 91.0) (61.8, 88.8) (6.8, 86.3) (63.4, 89.0) (27.4, 78.3) Grade 3/4 TEAEs (%) 75.0 73.5 63.2 73.5 64.5 - EMD – N EMD – Y <50% BMPC ≥50% BMPC Penta-refractory disease – N Penta-refractory disease - Y (n=84) (n=39) (n=89) (n=26) (n=71) (n=52) Median treatment duration (mo) 8.4 2.2 8.2 3.0 10.0 2.3 Receiving treatment at data cut-off (%) 38.1 25.6 38.2 26.9 42.3 23.1 ORR (%, 95% CI) 71.4 38.5 67.4 46.2 71.8 46.2 (60.5, 80.8) (23.4, 55.4) (56.7, 77.0) (26.6, 66.6) (59.9, 81.9) (32.2, 60.5) DOR rate at 12 mo (%, 95% CI) 73.8 73.4 72.0 81.5 74.7 71.9 (58.3, 84.3) (37.4, 90.8) (56.6, 82.7) (43.5, 95.1) (58.6, 85.3) (41.2, 88.4) Grade 3/4 TEAEs (%) 77.4 56.4 73.0 69.2 73.2 67.3 Keywords: Myeloma, Bispecific, Multiple myeloma, Clinical trial" @default.
• W4385698049 created "2023-08-10" @default.
• W4385698049 creator A5001145185 @default.
• W4385698049 creator A5005182505 @default.
• W4385698049 creator A5041161932 @default.
• W4385698049 creator A5044238802 @default.
• W4385698049 creator A5058940187 @default.
• W4385698049 creator A5065238694 @default.
• W4385698049 creator A5087641723 @default.
• W4385698049 creator A5089939702 @default.
• W4385698049 creator A5091231536 @default.
• W4385698049 date "2023-08-01" @default.
• W4385698049 modified "2023-10-01" @default.
• W4385698049 title "P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3" @default.
• W4385698049 doi "https://doi.org/10.1097/01.hs9.0000970532.16622.f0" @default.
• W4385698049 hasPublicationYear "2023" @default.
• W4385698049 type Work @default.
• W4385698049 citedByCount "0" @default.
• W4385698049 crossrefType "journal-article" @default.
• W4385698049 hasAuthorship W4385698049A5001145185 @default.
• W4385698049 hasAuthorship W4385698049A5005182505 @default.
• W4385698049 hasAuthorship W4385698049A5041161932 @default.
• W4385698049 hasAuthorship W4385698049A5044238802 @default.
• W4385698049 hasAuthorship W4385698049A5058940187 @default.
• W4385698049 hasAuthorship W4385698049A5065238694 @default.
• W4385698049 hasAuthorship W4385698049A5087641723 @default.
• W4385698049 hasAuthorship W4385698049A5089939702 @default.
• W4385698049 hasAuthorship W4385698049A5091231536 @default.
• W4385698049 hasBestOaLocation W43856980491 @default.
• W4385698049 hasConcept C121332964 @default.
• W4385698049 hasConcept C126322002 @default.
• W4385698049 hasConcept C141071460 @default.
• W4385698049 hasConcept C142424586 @default.
• W4385698049 hasConcept C143998085 @default.
• W4385698049 hasConcept C2776063141 @default.
• W4385698049 hasConcept C2776364478 @default.
• W4385698049 hasConcept C2778715236 @default.
• W4385698049 hasConcept C71924100 @default.
• W4385698049 hasConcept C72563966 @default.
• W4385698049 hasConcept C87355193 @default.
• W4385698049 hasConcept C90924648 @default.
• W4385698049 hasConceptScore W4385698049C121332964 @default.
• W4385698049 hasConceptScore W4385698049C126322002 @default.
• W4385698049 hasConceptScore W4385698049C141071460 @default.
• W4385698049 hasConceptScore W4385698049C142424586 @default.
• W4385698049 hasConceptScore W4385698049C143998085 @default.
• W4385698049 hasConceptScore W4385698049C2776063141 @default.
• W4385698049 hasConceptScore W4385698049C2776364478 @default.
• W4385698049 hasConceptScore W4385698049C2778715236 @default.
• W4385698049 hasConceptScore W4385698049C71924100 @default.
• W4385698049 hasConceptScore W4385698049C72563966 @default.
• W4385698049 hasConceptScore W4385698049C87355193 @default.
• W4385698049 hasConceptScore W4385698049C90924648 @default.
• W4385698049 hasIssue "S3" @default.
• W4385698049 hasLocation W43856980491 @default.
• W4385698049 hasLocation W43856980492 @default.
• W4385698049 hasOpenAccess W4385698049 @default.
• W4385698049 hasPrimaryLocation W43856980491 @default.
• W4385698049 hasRelatedWork W1790206647 @default.
• W4385698049 hasRelatedWork W1988934582 @default.
• W4385698049 hasRelatedWork W2072770520 @default.
• W4385698049 hasRelatedWork W2102372291 @default.
• W4385698049 hasRelatedWork W2111732928 @default.
• W4385698049 hasRelatedWork W2351796763 @default.
• W4385698049 hasRelatedWork W2531713994 @default.
• W4385698049 hasRelatedWork W2899586773 @default.
• W4385698049 hasRelatedWork W3031374739 @default.
• W4385698049 hasRelatedWork W3217566318 @default.
• W4385698049 hasVolume "7" @default.
• W4385698049 isParatext "false" @default.
• W4385698049 isRetracted "false" @default.
• W4385698049 workType "article" @default.